"id:ID","studyTitle","studyVersion","studyAcronym","uuid","id","studyRationale"
"821","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","2","H2Q-MC-LZZT","8ac17269-b2c4-4d43-9500-8487550af55c","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
